Prenatal diagnosis of thyroid hormone resistance

C. Asteria, O. Rajanayagam, T. N. Collingwood, L. Persani, R. Romoli, D. Mannavola, P. Zamperini, F. Buzi, F. Ciralli, V. K K Chatterjee, P. Beck-Peccoz

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

A 29-yr-old woman with pituitary resistance to thyroid hormones (PRTH) was found to harbor a novel point mutation (T337A) on exon 9 of the thyroid hormone receptor β (TRβ) gene. She presented with symptoms and signs of hyperthyroidism and was successfully treated with 3,5,3'-triiodothyroacetic acid (TRIAC) until the onset of pregnancy. This therapy was then discontinued in order to prevent TRIAC, a compound that crosses the placental barrier, from exerting adverse effects on normal fetal development. However, as the patient showed a recurrence of thyrotoxic features after TRIAC withdrawal, we sought to verify, by means of genetic analysis and hormone measurements, whether the fetus was also affected by RTH, in order to rapidly reinstitute TRIAC therapy, which could potentially be beneficial to both the mother and fetus. At 17 weeks gestation, fetal DNA was extracted from chorionic villi and was used as a template for PCR and restriction analysis together with direct sequencing of the TRβ gene. The results indicated that the fetus was also heterozygous for the T337A mutation. Accordingly, TRIAC treatment at a dose of 2.1 mg/day was restarted at 20 weeks gestation. The mother rapidly became euthyroid, and the fetus grew normally up to 24 weeks gestation. At 29 weeks gestation mild growth retardation and fetal goiter were observed, prompting cordocentesis. Circulating fetal TSH was very high (287 mU/L) with a markedly reduced TSH bioactivity (B/I: 1.1 ± 0.4 vs 12.7 ± 1.2), while fetal FT4 concentrations were normal (8.7 pmol/L; normal values in age- matched fetuses: 5-22 pmol/L). Fetal FT3 levels were raised (7.1 pmo/L; normal values in age-matched fetuses:

Original languageEnglish
Pages (from-to)405-410
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Volume84
Issue number2
DOIs
Publication statusPublished - 1999

Fingerprint

Thyroid Hormone Resistance Syndrome
Prenatal Diagnosis
Thyroid Hormones
Fetus
Thyroid Hormone Receptors
Acids
Pregnancy
Genes
Reference Values
Ports and harbors
Bioactivity
Cordocentesis
Mothers
Chorionic Villi
Exons
Fetal Growth Retardation
Goiter
Hormones
Hyperthyroidism
Fetal Development

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Asteria, C., Rajanayagam, O., Collingwood, T. N., Persani, L., Romoli, R., Mannavola, D., ... Beck-Peccoz, P. (1999). Prenatal diagnosis of thyroid hormone resistance. Journal of Clinical Endocrinology and Metabolism, 84(2), 405-410. https://doi.org/10.1210/jc.84.2.405

Prenatal diagnosis of thyroid hormone resistance. / Asteria, C.; Rajanayagam, O.; Collingwood, T. N.; Persani, L.; Romoli, R.; Mannavola, D.; Zamperini, P.; Buzi, F.; Ciralli, F.; Chatterjee, V. K K; Beck-Peccoz, P.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 84, No. 2, 1999, p. 405-410.

Research output: Contribution to journalArticle

Asteria, C, Rajanayagam, O, Collingwood, TN, Persani, L, Romoli, R, Mannavola, D, Zamperini, P, Buzi, F, Ciralli, F, Chatterjee, VKK & Beck-Peccoz, P 1999, 'Prenatal diagnosis of thyroid hormone resistance', Journal of Clinical Endocrinology and Metabolism, vol. 84, no. 2, pp. 405-410. https://doi.org/10.1210/jc.84.2.405
Asteria C, Rajanayagam O, Collingwood TN, Persani L, Romoli R, Mannavola D et al. Prenatal diagnosis of thyroid hormone resistance. Journal of Clinical Endocrinology and Metabolism. 1999;84(2):405-410. https://doi.org/10.1210/jc.84.2.405
Asteria, C. ; Rajanayagam, O. ; Collingwood, T. N. ; Persani, L. ; Romoli, R. ; Mannavola, D. ; Zamperini, P. ; Buzi, F. ; Ciralli, F. ; Chatterjee, V. K K ; Beck-Peccoz, P. / Prenatal diagnosis of thyroid hormone resistance. In: Journal of Clinical Endocrinology and Metabolism. 1999 ; Vol. 84, No. 2. pp. 405-410.
@article{eca2eeca3a4443af936ae8b4a8db6f7e,
title = "Prenatal diagnosis of thyroid hormone resistance",
abstract = "A 29-yr-old woman with pituitary resistance to thyroid hormones (PRTH) was found to harbor a novel point mutation (T337A) on exon 9 of the thyroid hormone receptor β (TRβ) gene. She presented with symptoms and signs of hyperthyroidism and was successfully treated with 3,5,3'-triiodothyroacetic acid (TRIAC) until the onset of pregnancy. This therapy was then discontinued in order to prevent TRIAC, a compound that crosses the placental barrier, from exerting adverse effects on normal fetal development. However, as the patient showed a recurrence of thyrotoxic features after TRIAC withdrawal, we sought to verify, by means of genetic analysis and hormone measurements, whether the fetus was also affected by RTH, in order to rapidly reinstitute TRIAC therapy, which could potentially be beneficial to both the mother and fetus. At 17 weeks gestation, fetal DNA was extracted from chorionic villi and was used as a template for PCR and restriction analysis together with direct sequencing of the TRβ gene. The results indicated that the fetus was also heterozygous for the T337A mutation. Accordingly, TRIAC treatment at a dose of 2.1 mg/day was restarted at 20 weeks gestation. The mother rapidly became euthyroid, and the fetus grew normally up to 24 weeks gestation. At 29 weeks gestation mild growth retardation and fetal goiter were observed, prompting cordocentesis. Circulating fetal TSH was very high (287 mU/L) with a markedly reduced TSH bioactivity (B/I: 1.1 ± 0.4 vs 12.7 ± 1.2), while fetal FT4 concentrations were normal (8.7 pmol/L; normal values in age- matched fetuses: 5-22 pmol/L). Fetal FT3 levels were raised (7.1 pmo/L; normal values in age-matched fetuses:",
author = "C. Asteria and O. Rajanayagam and Collingwood, {T. N.} and L. Persani and R. Romoli and D. Mannavola and P. Zamperini and F. Buzi and F. Ciralli and Chatterjee, {V. K K} and P. Beck-Peccoz",
year = "1999",
doi = "10.1210/jc.84.2.405",
language = "English",
volume = "84",
pages = "405--410",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - Prenatal diagnosis of thyroid hormone resistance

AU - Asteria, C.

AU - Rajanayagam, O.

AU - Collingwood, T. N.

AU - Persani, L.

AU - Romoli, R.

AU - Mannavola, D.

AU - Zamperini, P.

AU - Buzi, F.

AU - Ciralli, F.

AU - Chatterjee, V. K K

AU - Beck-Peccoz, P.

PY - 1999

Y1 - 1999

N2 - A 29-yr-old woman with pituitary resistance to thyroid hormones (PRTH) was found to harbor a novel point mutation (T337A) on exon 9 of the thyroid hormone receptor β (TRβ) gene. She presented with symptoms and signs of hyperthyroidism and was successfully treated with 3,5,3'-triiodothyroacetic acid (TRIAC) until the onset of pregnancy. This therapy was then discontinued in order to prevent TRIAC, a compound that crosses the placental barrier, from exerting adverse effects on normal fetal development. However, as the patient showed a recurrence of thyrotoxic features after TRIAC withdrawal, we sought to verify, by means of genetic analysis and hormone measurements, whether the fetus was also affected by RTH, in order to rapidly reinstitute TRIAC therapy, which could potentially be beneficial to both the mother and fetus. At 17 weeks gestation, fetal DNA was extracted from chorionic villi and was used as a template for PCR and restriction analysis together with direct sequencing of the TRβ gene. The results indicated that the fetus was also heterozygous for the T337A mutation. Accordingly, TRIAC treatment at a dose of 2.1 mg/day was restarted at 20 weeks gestation. The mother rapidly became euthyroid, and the fetus grew normally up to 24 weeks gestation. At 29 weeks gestation mild growth retardation and fetal goiter were observed, prompting cordocentesis. Circulating fetal TSH was very high (287 mU/L) with a markedly reduced TSH bioactivity (B/I: 1.1 ± 0.4 vs 12.7 ± 1.2), while fetal FT4 concentrations were normal (8.7 pmol/L; normal values in age- matched fetuses: 5-22 pmol/L). Fetal FT3 levels were raised (7.1 pmo/L; normal values in age-matched fetuses:

AB - A 29-yr-old woman with pituitary resistance to thyroid hormones (PRTH) was found to harbor a novel point mutation (T337A) on exon 9 of the thyroid hormone receptor β (TRβ) gene. She presented with symptoms and signs of hyperthyroidism and was successfully treated with 3,5,3'-triiodothyroacetic acid (TRIAC) until the onset of pregnancy. This therapy was then discontinued in order to prevent TRIAC, a compound that crosses the placental barrier, from exerting adverse effects on normal fetal development. However, as the patient showed a recurrence of thyrotoxic features after TRIAC withdrawal, we sought to verify, by means of genetic analysis and hormone measurements, whether the fetus was also affected by RTH, in order to rapidly reinstitute TRIAC therapy, which could potentially be beneficial to both the mother and fetus. At 17 weeks gestation, fetal DNA was extracted from chorionic villi and was used as a template for PCR and restriction analysis together with direct sequencing of the TRβ gene. The results indicated that the fetus was also heterozygous for the T337A mutation. Accordingly, TRIAC treatment at a dose of 2.1 mg/day was restarted at 20 weeks gestation. The mother rapidly became euthyroid, and the fetus grew normally up to 24 weeks gestation. At 29 weeks gestation mild growth retardation and fetal goiter were observed, prompting cordocentesis. Circulating fetal TSH was very high (287 mU/L) with a markedly reduced TSH bioactivity (B/I: 1.1 ± 0.4 vs 12.7 ± 1.2), while fetal FT4 concentrations were normal (8.7 pmol/L; normal values in age- matched fetuses: 5-22 pmol/L). Fetal FT3 levels were raised (7.1 pmo/L; normal values in age-matched fetuses:

UR - http://www.scopus.com/inward/record.url?scp=0032977512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032977512&partnerID=8YFLogxK

U2 - 10.1210/jc.84.2.405

DO - 10.1210/jc.84.2.405

M3 - Article

VL - 84

SP - 405

EP - 410

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 2

ER -